HC Wainwright & Co. Reiterates Buy on Travere Therapeutics, Maintains $47 Price Target

Benzinga · 11/28/2025 11:57
HC Wainwright & Co. analyst Joseph Pantginis reiterates Travere Therapeutics (NASDAQ:TVTX) with a Buy and maintains $47 price target.